Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation

International Journal of Hematology

Volumn 93, Issue 4, 2011, Pages 509-516

  Nakane, Takahiko ^a   Nakamae, Hirohisa ^a   Koh, Hideo ^a   Nakamae, Mika ^a   Hayashi, Yoshiki ^a   Nishimoto, Mitsutaka ^a   Yoshimura, Takuro ^a   Inoue, Eri ^a   Inoue, Atsushi ^a   Aimoto, Ran ^a   Aimoto, Mizuki ^a   Terada, Yoshiki ^a   Koh, Ki Ryang ^a   Yamane, Takahisa ^a   Hino, Masayuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marrow transplantation; Non relapse mortality; Reduced intensity conditioning; Unrelated donor

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; POLYMYXIN B; STEROID; SULFAMETHOXAZOLE; SULFATE; TRIMETHOPRIM; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADENOVIRUS; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BLEEDING; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CHIMERA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CYTOMEGALOVIRUS ANTIGENEMIA; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS PNEUMONIA; DIARRHEA; DONOR; ENDOTRACHEAL INTUBATION; ENGRAFTMENT; ENGRAFTMENT SYNDROME; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMOPHAGOCYTIC SYNDROME; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HLA MATCHING; HUMAN; IRRADIATION; JAPANESE; LIVER TOXICITY; LUNG MYCOSIS; LUNG TOXICITY; MALE; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS TOXICITY; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SHORT TANDEM REPEAT; SINGLE DRUG DOSE; SUBDURAL HEMATOMA; SURVIVAL; T CELL DEPLETION; UNRELATED DONOR; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS INFECTION; VIRUS REACTIVATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHIMERISM; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 79955939117     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0805-z     Document Type: Article

References (42)

1. Bornhäuser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001;7:2254-62. (Pubitemid 32751622)
2. Nagler A, Aker M, Or R, Naparstek E, Varadi G, Brautbar C, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-70. (Pubitemid 32223461)
3. Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100:3919-24. (Pubitemid 35402053)
4. Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 2005;19:7-12. (Pubitemid 40090068)
5. Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Br J Haematol. 2005;129:631-43. (Pubitemid 40825825)
6. Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation. 2006;82:913-9. (Pubitemid 44564037)
7. Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 2010;148:323-31.
8. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071-8. (Pubitemid 34525573)
9. Shaw BE, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA, et al. The impact of donor factors on primary nonengraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica. 2005;90:1562-9. (Pubitemid 41658770)
10. Lim ZY, Ho AY, Ingram W, Kenyon M, Pearce L, Czepulkowski B, et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol. 2006;135:201-9. (Pubitemid 44401617)
11. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620-9. (Pubitemid 36182543)
12. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-30. (Pubitemid 37122375)
13. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLAmatched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961-8. (Pubitemid 39038014)
14. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant. 2006;12:454-65. (Pubitemid 43380962)
15. Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, et al. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood. 2005;105:3035-41.
16. Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant. 2004;33:697-702. (Pubitemid 38499922)
17. Onishi Y, Mori S, Kusumoto S, Sugimoto K, Akahane D, Morita-Hoshi Y, et al. Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation. Int J Hematol. 2007;85:256-63. (Pubitemid 46686587)
18. Mizumoto C, Kanda J, Ichinohe T, Ishikawa T, Matsui M, Kadowaki N, et al. Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning. Int J Hematol. 2009;89:538-45.
19. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855-64.
20. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204-13. (Pubitemid 27444217)
21. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009;15:1422-30.
22. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-63. (Pubitemid 34627201)
23. Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, et al. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:913-9. (Pubitemid 351985029)
24. Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, Itala M, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26:5094-100.
25. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200-6.
26. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628-33.
27. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-8.
28. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-9.
29. Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009;15:704-17.
30. Fuji S, Fukuda T, Kim SW, Usui E, Kurosawa S, Yokoyama H, et al. Low-dose ATG-F reduces non-relapse mortality after reduced-intensity bone marrow transplantation from an unrelated donor: a single-center analysis of 65 patients. Blood. 2007;110:5070. (ASH annual meeting abstracts).
31. Rodriguez R, Parker P, Nademanee A, Smith D, O'Donnell MR, Stein A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant. 2004;33:1123-9. (Pubitemid 38786502)
32. Ho VT, Kim HT, Liney D, Milford E, Gribben J, Cutler C, et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:845-50.
33. Inamoto Y, Oba T, Miyamura K, Terakura S, Tsujimura A, Kuwatsuka Y, et al. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor. Int J Hematol. 2006;83:356-62. (Pubitemid 43807583)
34. Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, et al. Grupo Español de Trasplante Hematopoyético (GETH). Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2008;14:664-71.
35. Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009;114:3956-9.
36. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119-26. (Pubitemid 46743372)
37. Kim SW, Hino M, Hatanaka K, Ueda Y, Tanosaki R, Hirokawa M, et al. Reduced intensity conditioning (RIC) with cladribine, busulfan and 4 Gy total body irradiation (TBI) for bone marrow transplantation (BMT) from an HLA-matched unrelated donor (URD): a prospective multi-institutional clinical trial. Blood. 2006;108:5397. (ASH annual meeting abstracts).
38. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454-62. (Pubitemid 46421890)
39. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40:541-7. (Pubitemid 47382124)
40. Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006;20:707-14.
41. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graftversus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26:577-84. (Pubitemid 351264351)
42. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675-87.